Michael Mauro, MD, Memorial Sloan Kettering Cancer Center, New York, NY, emphasizes the importance of risk stratifying patients with CML for cardiovascular adverse events when choosing first-line therapy, possibly through a full cardiovascular evaluation. Based on the assessed cardiovascular risk, an appropriate TKI can then be selected. According to Dr Mauro, this first step is critical to management of cardiovascular risk throughout the possible long-term use of TKIs.